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Hexavalent chromium [Cr(VI)] compounds 
are classified as human carcinogens [Cohen 
et al. 1993; International Agency for Research 
on Cancer (IARC) 1990; National Toxicology 
Program (NTP) 1998], based on increased 
incidences of lung cancers in animals and 
humans after inhalation exposures. Inhalation 
exposures occur primarily in occupational set-
tings. The highest exposure to Cr(VI) occurs 
occupationally among workers involved in 
chrome plating, chromate production, and 
stainless steel welding.
As a result of industrial contamination, 
concentrations of Cr(VI) in the drinking 
water and soil may be higher than concen-
trations resulting from natural sources alone, 
causing ingestion of higher concentrations by 
populations residing near these locations than 
by the general population. A Cr(VI) concen-
tration of 580 µg/L was found in a ground-
water monitoring well in Hinkley, California 
(Pellerin and Booker 2000). Detectable lev-
els of Cr(VI) have been reported in approxi-
mately 30% of the drinking water sources 
monitored in California, which has a 1 µg/L 
detection limit for purposes of reporting 
[California Department of Public Health 
(CDPH) 2007a]; 86% of those sources had 
peak concentrations of ≤ 10 µg/L. The U.S. 
Environmental Protection Agency (EPA) has 
set a maximum contaminant level of 100 µg/L 
for total chromium in drinking water (U.S. 
EPA 2003). The limit in California and 
numerous other states is 50 µg/L of total chro-
mium in drinking water (CDPH 2007b).
The toxicity of Cr(VI) in humans and ani-
mals has been reviewed extensively (Agency for 
Toxic Substances and Disease Registry 2000; 
Costa 1997; Costa and Klein 2006; U.S. EPA 
1998). We identified only one lifetime animal 
carcinogenicity study in the literature in which 
Cr(VI) was administered in the drinking water 
(Borneff et al. 1968). Further analysis of the 
data (Sedman et al. 2006) revealed that in 
three generations of female NMRI mice, the 
combined incidences of benign and malig-
nant forestomach neoplasms were increased 
over controls; this study has several limita-
tions, including high early mortality in the F0 
generation as a result of ectromelia (mouse-
pox) virus. A review of the few epidemiologic 
studies that evaluated populations that were 
exposed to Cr(VI) in drinking water or in soil 
or slag fill concluded that these studies did not 
provide definitive evidence of an increase in 
cancer incidence or mortality rates (Proctor 
et al. 2002). However, a retrospective mortal-
ity study in China found higher incidences of 
lung and stomach neoplasms in people living 
near a chromium smelting plant compared 
with the general population (Zhang and Li 
1987); statistical analysis of these data sup-
ported this conclusion (Beaumont et al. 2008; 
Sedman et al. 2006).
Because of concerns over its presence in 
drinking water source supplies, its potential 
health effects, including carcinogenicity, and 
the lack of adequate carcinogenicity studies by 
the oral route, the California Congressional 
Delegation, California Environmental 
Protection Agency, and California Department 
of Health Services nominated Cr(VI) to the 
NTP for toxicity and carcinogenicity testing. 
We selected sodium dichromate dihydrate 
(SDD) for testing because it is the primary base 
material for the production of chromium com-
pounds, is widely used in industrial applica-
tions, and is the most water-soluble chromate.
The NTP previously conducted 3-month 
toxicity studies of SDD administered in 
drinking water (NTP 2007). F344/N rats 
and B6C3F1 mice were exposed to 0, 62.5, 
125, 250, 500, or 1,000 mg SDD/L. In these 
studies, both rats and mice had reduced body 
weight and water consumption and microcytic 
hypochromic anemia; the anemia was more 
severe in rats. Exposure-related histopathologic 
lesions included ulcers, epithelial hyper  plasia, 
and squamous metaplasia in the glandular 
stomach of rats; epithelial hyperplasia of the 
duodenum of mice; and histiocytic cellular 
infiltration in the liver, duodenum, and pan-
creatic lymph node of rats and in the duode-
num and mesenteric lymph node of mice.
We selected exposure concentrations for 
the 2-year studies of SDD after review of 
the 3-month toxicity study data. The highest 
exposure concentration for the 2-year stud-
ies in rats and mice was limited by toxicity 
observed in the 3-month studies (NTP 2007), 
and a wider spacing of exposure concentra-
tions was selected to extend the dose–response 
curve. We added an additional low-exposure 
group [5 mg Cr(VI)/L] to the 2-year studies 
to provide a concentration closer to human 
exposure through contaminated drinking 
water. In this report we present the primary 
findings of the NTP chronic oral toxicity and 
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Ba c k g r o u n d: Hexavalent chromium [Cr(VI)] is a human carcinogen after inhalation exposure. 
Humans also ingest Cr(VI) from contaminated drinking water and soil; however, limited data exist 
on the oral toxicity and carcinogenicity of Cr(VI).
oB j e c t i v e: We characterized the chronic oral toxicity and carcinogenicity of Cr(VI) in rodents.
Me t h o d s : The National Toxicology Program (NTP) conducted 2-year drinking water studies of 
Cr(VI) (as sodium dichromate dihydrate) in male and female F344/N rats and B6C3F1 mice.
re s u l t s: Cr(VI) exposure resulted in increased incidences of rare neoplasms of the squamous epi-
thelium that lines the oral cavity (oral mucosa and tongue) in male and female rats, and of the epi-
thelium lining the small intestine in male and female mice. Cr(VI) exposure did not affect survival 
but resulted in reduced mean body weights and water consumption, due at least in part to poor pal-
atability of the dosed water. Cr(VI) exposure resulted in transient microcytic hypochromic anemia 
in rats and microcytosis in mice. Nonneoplastic lesions included diffuse epithelial hyperplasia in the 
duodenum and jejunum of mice and histiocytic cell infiltration in the duodenum, liver, and mesen-
teric and pancreatic lymph nodes of rats and mice.
co n c l u s i o n s: Cr(VI) was carcinogenic after administration in drinking water to male and female 
rats and mice.
key w o r d s : anemia, cancer, hexavalent chromium, histiocytic cellular infiltration, National Toxicology 
Program, oral cavity, small intestine. Environ Health Perspect 117:716–722(2009).  doi:10.1289/
ehp.0800208 available via http://dx.doi.org/ [Online 31 December 2008]Oral carcinogenicity of hexavalent chromium
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carcinogenesis studies of Cr(VI) in male and 
female rats and mice; a more detailed report 
on these studies is available as an NTP techni-
cal report (NTP 2008a).
Materials and Methods
Chemical and dose formulations. SDD (CAS 
7789-12-0) was obtained from Aldrich 
Chemical Company (Milwaukee, WI). The 
purity was determined using differential scan-
ning calorimetry, titration of the dichromate 
ion with sodium thiosulfate and potassium 
ferrocyanide, speciation of the chromium ions 
using liquid chromatography/inductively cou-
pled plasma-mass spectrometry, and poten-
tiometric titrimetric analysis with sodium 
thiosulfate. Based on these analyses, the overall 
purity was ≥ 99.7%. The dose formulations 
were prepared approximately every 2 weeks 
by mixing SDD with tap water and stored at 
room temperature in sealed containers pro-
tected from light. The dose formulations were 
stable for 42 days under these conditions. 
Periodic analysis by ultraviolet spectroscopy 
with detection at 350–390 nm confirmed that 
all dose formulations varied by < 10% of the 
target concentrations.
Animals and animal maintenance. The 
studies were conducted at Southern Research 
Institute (Birmingham, AL). Male and female 
F344/N rats and B6C3F1 mice were obtained 
from Taconic Farms (Germantown, NY). Rats 
and mice were quarantined for 14 days, and 
were 6–7 weeks of age at the beginning of the 
studies. Animals were distributed randomly 
into groups of approximately equal initial mean 
body weights and identified by tail tattoo. Rats 
and mice were housed one (male mice), three 
(male rats), or five (female rats and mice) to 
a cage. Feed (irradiated NTP-2000 wafers; 
Zeigler Brothers, Inc., Gardners, PA) and tap 
water were available ad libitum. Animals were 
killed by carbon dioxide asphyxiation.
Animal use was in accordance with the 
U.S. Public Health Service policy on humane 
care and use of laboratory animals and the 
Guide for the Care and Use of Laboratory 
Animals (National Research Council 1996). 
Animals were treated humanely and with 
regard for alleviation of suffering. These 
studies were conducted in compliance with 
the Food and Drug Administration Good 
Laboratory Practice Regulations (Food and 
Drug Administration 1987).
Study design. Groups of 50 male and 
50 female rats and mice were exposed to SDD 
in drinking water at concentrations of 0, 14.3, 
57.3, 172, or 516 mg/L (male and female rats 
and female mice) or 0, 14.3, 28.6, 85.7, or 
257.4 mg/L (male mice) for 105–106 weeks. 
Table 1 shows corresponding Cr(VI) concen-
trations. Water consumption was recorded 
weekly for the first 13 weeks and every 4 weeks 
thereafter, with each water consumption 
measurement covering a 7-day period. Animals 
were weighed initially, weekly for the first 13 
weeks, at 4-week intervals thereafter, and at 
the end of the studies. Animals were observed 
twice daily and clinical findings were recorded 
at 4-week intervals beginning at week 5.
Complete necropsies and microscopic 
examinations were performed on all core study 
rats and mice. At necropsy, all organs and tis-
sues were examined for grossly visible lesions, 
and all protocol-required tissues were fixed and 
preserved in 10% neutral buffered formalin 
(eyes were initially fixed in Davidson’s solu-
tion), trimmed and processed, embedded in 
paraffin, sectioned to a thickness of 4–6 µm, 
and stained with hematoxylin and eosin (H&E) 
for microscopic examination. For all paired 
organs (e.g., adrenal gland, kidney, ovary), 
samples from each organ were examined. The 
entire gastrointestinal tract was opened and 
potential lesions were collected for microscopic 
evaluation. Oral mucosa and tongue are not 
protocol-required tissues; however, because 
gross lesions in these tissues were diagnosed 
as neoplasms, the oral mucosa and tongue 
of all animals were evaluated histologically. 
Additional details regarding the pathology data 
generation, quality assurance review, and NTP 
pathology working group are available in the 
NTP technical report (NTP 2008a). Details of 
these review procedures have been described, in 
part, by Maronpot and Boorman (1982) and 
Boorman et al. (1985). For subsequent analyses 
of the pathology data, the decision of whether 
to evaluate the diagnosed lesions for each tissue 
type separately or combined was based on the 
guidelines of McConnell et al. (1986).
Hematology and clinical chemistry were 
evaluated in additional groups of 10–16 male 
rats and female mice on days 4 (male rats 
only) and 22 and at 3, 6, and 12 months. At 
these time points, rats and mice were anes-
thetized with CO2/O2, and blood was taken 
from the retroorbital sinus.
Statistical methods. We estimated the 
probability of survival by the product-limit pro-
cedure of Kaplan and Meier (1958). Animals 
found dead of other than natural causes or 
missing were censored from the survival analy-
ses; animals dying from natural causes were not 
censored. Statistical analyses for possible dose-
related effects on survival used Cox’s (1972) 
method for testing two groups for equality and 
Tarone’s (1975) life table test to identify dose-
related trends. All reported p-values for the 
survival analyses are two sided.
We used the poly-k test (Bailer and Portier 
1988; Piegorsch and Bailer 1997; Portier and 
Bailer 1989) to assess neoplasm and non-
neoplastic lesion incidence. This test is a sur-
vival-adjusted quantal-response procedure that 
modifies the Cochran-Armitage linear trend 
test to take survival differences into account; 
we used a value of k = 3 in the analysis of site-
specific lesions. Tests of significance included 
pairwise comparisons of each exposed group 
with controls and a test for an overall exposure-
related trend. We used continuity-corrected 
poly-3 tests in the analysis of lesion incidence, 
and reported p-values are one sided. Sub- and 
supra  linear trends across doses for intestinal 
tumor rates were assessed with lack-of-fit tests 
for the linear regression of intestinal tumor rate 
on dose (Neter et al. 1996).
We analyzed hematology and clinical 
chemistry data, which typically have skewed 
distributions, using the modified (Dunn 
1964; Williams 1986) nonparametric multiple 
Table 1. Concentrations in drinking water and average daily ingested doses of SDD and Cr(VI) after expo-
sure for 2 years.
  Concentration in drinking water (mg/L)  Average daily ingested dose (mg/kg)
Animals  SDD  Cr(VI)a  SDDb  Cr(VI)c
Male rats  0  0  0  0
  14.3  5  0.6  0.2
  57.3  20  2.2  0.8
  172  60  6  2.1
  516  180  17  5.9
Female rats  0  0  0  0
  14.3  5  0.7  0.2
  57.3  20  2.7  0.9
  172  60  7  2.4
  516  180  20  7.0
Male mice  0  0  0  0
  14.3  5  1.1  0.4
  28.6  10  2.6  0.9
  85.7  30  7  2.4
  257.4  90  17  5.9
Female mice  0  0  0  0
  14.3  5  1.1  0.4
  57.3  20  3.9  1.4
  172  60  9  3.1
  516  180  25  8.7
aCalculated using the drinking water concentration of SDD and the percent mass of Cr(VI) in SDD. bCalculated using body 
weight and water consumption data. cCalculated using the average daily dose of SDD and the percent mass of Cr(VI) in SDD.Stout et al.
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comparison methods of Shirley (1977). We 
used Jonckheere’s test (Jonckheere 1954) to 
assess the significance of the dose-related trends 
and to determine whether a trend-sensitive 
test (Shirley 1977; Williams 1986) was more 
appropriate for pairwise comparisons than a 
test that does not assume a monotonic dose-
related trend (Dunn 1964; Dunnett 1955). 
Before statistical analysis, we examined extreme 
values identified by the outlier test of Dixon 
and Massey (1957) and eliminated implausible 
values from the analysis.
Results
Oral cavity neoplasms in rats. Male and 
female rats showed significantly increased 
incidences of highly aggressive neoplasms of 
the squamous epithelium that lines the oral 
cavity (oral mucosa and tongue) at 516 mg/L 
(Table 2). Specifically, we observed increases 
for squamous cell carcinoma in the oral 
mucosa and for squamous cell papilloma or 
carcinoma (combined) of the oral mucosa or 
tongue of male and female rats at 516 mg/L. 
There were squamous cell carcinomas in the 
oral mucosa of two 172 mg/L female rats; this 
incidence exceeded the historical control ranges 
for drinking water studies and for all routes of 
administration (Table 2). We did not observe 
non-neoplastic lesions in the oral mucosa.
Microscopically, the squamous cell carci-
nomas were highly invasive, irregular masses. 
Typically, the carcinomas appeared to origi-
nate in the oral mucosa of the palate adja-
cent to the upper molar teeth (Figure 1A, B); 
in some animals they invaded the tongue, 
Harderian gland, and the soft tissues sur-
rounding the nose, and in one case it pene-
trated the maxilla and invaded the brain. The 
squamous cell papillomas of the oral mucosa 
and tongue were exophytic masses that 
projected from the mucosa and consisted of 
irregular papillary proliferations of mature 
squamous epithelium supported by a core of 
fibrovascular stroma (Figure 1C).
Small intestine neoplasms and hyperpla-
sia in mice. Both males and females showed 
a clear exposure concentration response for 
increased incidences of adenoma or carcinoma 
(combined) at all sites (combined) of the small 
intestine (duodenum, jejunum, or ileum; 
Table 3). These increases were significant at 
85.7 and 257.4 mg/L in males and at 172 and 
516 mg/L females, the two highest exposure 
concentrations in each sex. In addition, the 
incidence in 57.3 mg/L females exceeded the 
historical control ranges for drinking water 
studies and for all routes of administration 
(Table 3). These increases were driven primar-
ily by significant increases in the incidences 
of adenoma of the duodenum in 257.4 mg/L 
males and in 172 and 516 mg/L females; the 
number of mice with multiple adenomas was 
also significantly increased at the high dose 
in both sexes (data not shown). In females, 
the incidence of carcinoma in the duodenum 
was significantly increased at 516 mg/L. In 
the jejunum, the incidence of adenoma was 
increased in 516 mg/L females. For both 
males and females, we tested the combined 
incidence of adenoma and carcinoma for 
departures from a linear dose response (data 
not shown). For males, the trend was linear, 
with no significant departure from linearity. 
For females, the response was supralinear with 
a significant departure from linearity.
Adenomas were discrete, broad based, 
focally extensive, plaquelike areas of prolif-
erating glandular epithelium that thickened 
the mucosa and protruded into the lumen 
(Figure 1D). Carcinomas were sessile, plaque-
like neoplasms distinguished from adenomas 
by extensive invasion and effacement of the 
mucosa, underlying submucosa, and muscle 
layers (Figure 1E).
Low incidences of focal epithelial hyper-
plasia occurred in the duodenum of exposed 
male and female mice (Table 4). Although 
the increased incidences were not exposure 
concentration related or statistically signifi-
cant, we considered this lesion a preneoplastic 
lesion related to exposure to SDD because of 
its morphologic similarities to adenoma. Focal 
epithelial hyperplasias were focal areas of pro-
liferating glandular epithelium distinguished 
from adenomas because they were smaller, 
less discrete, and confined to the superficial 
mucosal epithelium (Figure 1F).
The incidences of diffuse epithelial hyper-
plasia were significantly increased in the duo-
denum of all exposed groups of male and 
female mice (Table 4). In the jejunum, the 
incidence of diffuse epithelial hyper  plasia was 
significantly increased in 516 mg/L females. In 
contrast to those of the controls (Figure 1G), 
the duodenums of exposed mice had short, 
broad, blunt villi and generalized mucosal 
hypercellularity that was particularly promi-
nent in the villi (Figure 1H).
Histiocytic infiltration in rats and mice. 
We found significant increases in histiocytic 
cell infiltration in the duodenum and mesen-
teric lymph node of rats and mice of both 
sexes, in the jejunum of female mice, in the 
liver of male and female rats and female mice, 
and in the pancreatic lymph node of female 
rats and male and female mice; these data 
are presented in detail in the NTP technical 
report (NTP 2008a).
The infiltrating histiocytes were morpho-
logically similar in tissues of rats and mice. 
Histiocytic infiltrates were characterized by 
the presence of individual, small clusters, and 
Table 2. Squamous cell neoplasms of the oral cavity (oral mucosa and tongue) of F344/N rats exposed to SDD for 2 years in drinking water.
  Historical control incidencea (range)  Incidence/no. of animals necropsied (survival-adjusted percent incidence)b
Tissue/neoplasm  Drinking water  All routes  0 mg/L  14.3 mg/L  57.3 mg/L  172 mg/L  516 mg/L
Males
Oral mucosa
  Carcinoma  0/350  5/1,499 (0–2%)  0/50#  0/50  0/49  0/50  6/49 (13.6)*
Tongue
  Papilloma  NDc  ND  0/50  0/50  0/49  0/50  1/49 (2.3)
  Carcinoma  ND  ND  0/50  1/50 (2.4)  0/49  0/50  0/49
Oral mucosa or tongue
  Papilloma or carcinoma (combined)  1/350 (0–2%)  10/1,499 (0–2%)  0/50#  1/50 (2.4)  0/49  0/50  7/49 (15.7)**
Females
Oral mucosa
  Carcinoma  0/300  5/1,400 (0–2%)  0/50#  0/50  0/50  2/50d (4.6)  11/50 (23.9)#
Tongue
  Papilloma  ND  ND  1/50 (2.2)  1/50 (2.3)  0/50  0/50  0/50
  Carcinoma  ND  ND  0/50  0/50  0/50  1/50 (2.3)  0/50
Oral mucosa or tongue
  Papilloma or carcinoma (combined)  4/300 (0–2%)  15/1,400 (0–6%)  1/50 (2.2)#  1/50 (2.3)  0/50  2/50e (4.6)  11/50 (23.9)**
ND, not determined.
aThe NTP historical database contains all studies that use the NTP-2000 diet with histopathology findings completed within the most recent 5-year period, including the present study.
bCalculated using the poly-3 test. cHistorical control incidences are not determined for the tongue because it is not an NTP protocol-required tissue. dThe incidence exceeded the his-
torical control range for both drinking water studies and all routes but was not significantly increased compared with the concurrent control. eThe incidence exceeded the historical 
control range for drinking water studies but was not significantly increased compared with the concurrent control. *p ≤ 0.05, **p ≤ 0.01, and #p ≤ 0.001 compared with the control group 
by poly-3 test or a significant trend if assigned to a control group.Oral carcinogenicity of hexavalent chromium
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sometimes syncytia of large histiocytes (mac-
rophages) within the sinusoids of the liver and 
lymph nodes and the lamina propria at the tips 
of the duodenal and jejunal villi. In the lymph 
nodes, the histiocytic infiltrates occurred as 
expansive sheets that in some cases replaced 
much of the lymph node parenchyma. The 
biological significance and cause of the histio-
cytic cellular infiltrates are unknown.
Hematology in rats and mice. In rats, an 
exposure-related decrease in mean cell vol-
umes, mean cell hemoglobin concentrations, 
hematocrits, hemoglobin concentrations, and 
erythrocyte counts and increase in reticulocyte 
counts were indicative of erythrocyte micro-
cytic, hypochromic, responsive anemia; these 
data are presented in detail in the NTP tech-
nical report (NTP 2008a). The anemia was 
most prominent early in the study (22 days to 
3 months). Microscopic evaluations of blood 
smears demonstrated increased poikilocytes, 
erythrocyte fragments/schizocytes, keratocytes, 
erythrocyte hypochromia, and microcytes that 
suggested increased erythrocyte injury or turn-
over. This effect was more prominent on day 22 
and at 3 months than at 6 or 12 months, which 
may have been either a result of the animals 
adapting to exposure or a result of the decreased 
Cr(IV) ingestion per unit body weight with 
longer exposure durations. Mice demonstrated 
a similar, but less severe, effect on erythron.
In life effects in rats and mice. Survival, 
body weight, and water consumption data 
are presented in detail in the NTP techni-
cal report (NTP 2008a). Survival of exposed 
groups of male and female rats and mice 
was similar to that of the respective control 
groups. Mean body weights compared with 
controls were decreased in male and female 
rats and mice. In rats, mean body weights of 
516 mg/L males and females were less than 
those of controls throughout the study and 
by the end of the study were 12% (males) or 
11% (females) less than the controls. Mean 
body weights of 257.4 mg/L male mice were 
less than controls for the first 4 months of the 
study but were only slightly less (6%) by the 
end of the study. Mean body weights were 
less than the controls from months 3 to 12 
in 172 mg/L female mice and from month 
2 until the end of the study in 516 mg/L 
females. By the end of the study, mean body 
weights were < 8% of controls in 172 mg/L 
females and 15% less in 516 mg/L females.
We attributed the lower body weights partly 
to poor palatability of the dosed water and 
consequent reductions in water consumption 
rather than direct toxic effects of SDD expo-
sure. Water consumption by male and female 
rats and mice exposed to the two highest con-
centrations was that by the controls throughout 
the study. No clinical findings were attributed 
to SDD exposure in rats or mice. When we 
adjusted water consumption for body weight 
Figure 1. (A and B) Male rat given 516 mg/L SDD for 2 years. (A) Low magnification of a section of the nasal 
cavity demonstrating the location of squamous cell carcinoma (arrows) arising from the oral mucosa of 
the soft palate; the neoplasm has invaded the adjacent submucosal tissue and surrounded a molar tooth. 
(B) Higher magnification demonstrating the malignant features of the squamous cell carcinoma; islands 
and cords of dysplastic squamous epithelium (arrows) are surrounded by dense proliferative connective 
tissue stroma. (C) Female rat given 14.3 mg/L SDD for 2 years; squamous cell carcinoma projects from the 
dorsal mucosal surface of the tongue (arrows). (D) Female mouse given 516 mg/L SDD for 2 years; adenoma 
of the duodenum (arrows) has distorted and replaced a segment of the mucosa and protruded into the 
lumen. Normal mucosa is visible opposite the adenoma. (E) Male mouse given 257.4 mg/L SDD for 2 years; 
carcinoma of the duodenum (arrows) has effaced the mucosa, invading the submucosa, muscle layers, and   
pancreas. (F) Male mouse given 172 mg/L SDD for 2 years; focal hyperplasia of the duodenum (arrows) is 
present in the superficial mucosa. (G) Control female mouse; duodenum demonstrates normal microscopic 
anatomy. Note tall, slender villi (arrows) lined by a single layer of tall columnar epithelial cells. (H) Female 
mouse given 516 mg/L SDD for 2 years; diffuse hyperplasia is present in the duodenum. Duodenal villi are 
short, wide, and blunt and lined by hyperplastic epithelial cells that are piling up along the villi (arrows). Note 
histiocyte infiltrates expanding the lamina propria at the tips of the villi (asterisks). All sections are stained 
with hematoxylin and eosin. Bars: A and C, 500 µm; B and F, 100 µm; D and E, 200 µm; G and H, 50 µm.Stout et al.
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(data not shown), dosed male and female rats 
and female mice drank approximately the same 
quantities of water per gram of body weight 
as did the controls after the first 20 weeks on 
study. Male mice exposed to 257.4 mg/L drank 
less water per gram of body weight than did the 
controls throughout the study.
Discussion
Humans are exposed to Cr(VI) through inges-
tion of contaminated water and soil; however, 
few data exist on the oral toxicity and carcinoge-
nicity of Cr(VI). The NTP conducted 3-month 
(NTP 2007) and 2-year (NTP 2008a) studies 
of SDD administered in the drinking water 
to F344/N rats and B6C3F1 mice, to provide 
data on the potential for toxic and carcinogenic 
effects after ingestion of Cr(VI).
Chronic administration of SDD in drink-
ing water did not affect survival or produce 
clinical signs of toxicity in rats or mice. We 
observed exposure-related reductions in body 
weight gain and water consumption for rats 
and mice in the highest exposure groups 
and attributed these changes partly to poor 
palat  ability of the dosed water. Several lines 
of evidence suggest that the animals were not 
dehydrated, including analysis of the water con-
sumption data normalized to body weight and 
the complete lack of clinical observations or 
hematologic or clinical chemistry effects (NTP 
2008a) that typically indicate   dehydration.
The NTP concluded that the exposure 
concentration-related significant increases in 
epithelial neoplasms of the upper alimentary 
tract (oral cavity) in male and female rats and 
of the lower alimentary tract (small intestine) 
in male and female mice provided clear evi-
dence of carcinogenic activity of SDD in male 
and female rats and mice. We based this con-
clusion on the increased neoplasm incidences 
relative to concurrent controls and the rarity 
of these neoplasms (Tables 2 and 3) in his-
torical controls. In both rats and mice, this 
conclusion was strengthened by similarities 
between the sexes. We observed no increases 
in nonneoplastic histopathologic lesions in 
either species suggestive of overt tissue dam-
age due to the oxidant properties of Cr(VI).
We observed obvious species differences 
in the target tissues for the development of 
neoplasms between rats and mice. Of the 
21 chemicals that have caused neoplasms of 
the oral cavity in NTP studies, none produced 
these neoplasms in male mice and only one, 
1,2,3-trichloropropane (NTP 1993), produced 
oral cavity neoplasms in female mice, demon-
strating a greater sensitivity to the develop-
ment of oral cavity neoplasms in rats relative to 
mice. Although slightly more common in rats, 
exposure-related increases of small intestine 
neoplasms in NTP studies are relatively rare 
in both species. The 2-year study of captan 
(National Cancer Institute 1977) is the only 
other study performed by the NTP in B6C3F1 
mice in which both benign and malignant 
intestinal neoplasms of epithelial origin have 
Table 3. Epithelial neoplasms of the small intestine in B6C3F1 mice exposed to SDD in drinking water for 2 years.
  Historical control incidencea (range)
Tissue/neoplasm  Drinking water  All routes  Incidence/no. of animals necropsied (survival-adjusted % incidence)b
Males
Concentration (mg/L)      0  14.3  28.6  85.7  257.4
Duodenum
  Adenoma (includes multiple)  6/299 (0–6%)  9/1,549 (0–6%)  1/50 (2.2)#  0/50  1/50 (2.3)  5/50c (10.8)  15/50 (32.9)#
  Carcinoma  1/299 (0–2%)  3/1,549 (0–4%)  0/50*  0/50  0/50  2/50d (4.3)  3/50c (6.8)
Jejunum 
  Adenoma  0/299  1/1,549 (0–2%)  0/50**  0/50  0/50  0/50  3/50c (6.8)
  Carcinoma (includes multiple)  5/299 (0–4%)  25/1,549 (0–8%)  0/50  2/50 (4.5)  0/50  1/50 (2.2)  2/50 (4.6)
Duodenum, jejunum, or ileum (combined)
  Adenoma  6/299 (0–6%)  10/1,549 (0–6%)  1/50 (2.2)#  1/50 (2.3)  1/50 (2.3)  5/50c (10.8)  17/50 (37.2)#
  Carcinoma  6/299 (0–4%)  30/1,549 (0–8%)  0/50*  2/50 (4.5)  1/50 (2.3)  3/50d (6.5)  5/50 (11.4)*
 Adenoma or carcinoma (combined)  11/299 (0–10%)  39/1,549 (0–10%)  1/50 (2.2)#  3/50 (6.8)  2/50 (4.6)  7/50 (15.1)*  20/50 (43.8)#
Females
Concentration (mg/L)      0  14.3  57.3  172  516
Duodenum
  Adenoma (includes multiple)  1/350 (0–2%)  3/1,648 (0–2%)  0/50#  0/50  2/50c (4.2)  13/50 (27.8)#  12/50 (25.2)#
  Carcinoma  0/350  1/1,648 (0–2%)  0/50#  0/50  0/50  1/50d (2.1)  6/50 (12.6)*
Jejunum 
  Adenoma (includes multiple)  0/350  0/1,648  0/50**  1/50c (2.2)  0/50  2/50c (4.3)  5/50 (10.6)*
  Carcinoma  2/350 (0–2%)  5/1,648 (0–2%)  1/50 (2.2)  0/50  2/50c (4.2)  2/50c (4.3)  1/50 (2.1)
Duodenum, jejunum, or ileum (combined)
  Adenoma  1/350 (0–2%)  3/1,648 (0–2%)  0/50#  1/50 (2.2)  2/50c (4.2)  15/50 (32.0)#  16/50 (33.7)#
  Carcinoma  3/350 (0–2%)  8/1,648 (0–2%)  1/50 (2.2)#  0/50  2/50c (4.2)  3/50c (6.4)  7/50 (14.7)*
  Adenoma or carcinoma (combined)  4/350 (0–4%)  11/1,648 (0–4%)  1/50 (2.2)#  1/50 (2.2)  4/50c (8.3)  17/50 (36.3)#  22/50 (45.9)#
aThe NTP historical database contains all studies that use the NTP-2000 diet with histopathology findings completed within the most recent 5-year period, including the present study. 
bCalculated using the poly-3 test. cThe incidence exceeded the historical control range for both drinking water studies and all routes but was not significantly increased compared 
with the concurrent control. dThe incidence exceeded the historical control range for drinking water studies but was not significantly increased compared with the concurrent control. 
*p ≤ 0.05, **p ≤ 0.01, and #p ≤ 0.001 compared with control group by poly-3 test or a significant trend if assigned to a control group. 
Table 4. Focal and diffuse hyperplasia of the small intestine in B6C3F1 mice exposed to SDD in drinking 
water for 2 years.
Tissue  Incidence/no. of animals necropsied (mean severity)a 
Males
Concentration (mg/L)  0   14.3  28.6  85.7  257.4
Duodenum
  Epithelium, hyperplasia
  Focal  0/50  0/50  0/50  1/50 (3.0)  2/50 (3.5)
  Diffuse  0/50  11/50** (2.0)  18/50** (1.6)  42/50** (2.1)  32/50** (2.1)
Females
Concentration (mg/L)  0  14.3  57.3  172  516
Duodenum
  Epithelium, hyperplasia
  Focal  0/50  0/50  1/50 (2.0)  2/50 (3.0)  0/50
  Diffuse  0/50  16/50** (1.6)  35/50** (1.7)  31/50** (1.6)  42/50** (2.2)
Jejunum
  Epithelium, hyperplasia
  Diffuse  0/50  2/50 (2.0)  1/50 (2.0)  0/50  8/50** (1.9)
aMean severity: 1, minimal; 2, mild; 3, moderate; 4, marked. **p ≤ 0.01 by poly-3 test.Oral carcinogenicity of hexavalent chromium
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been definitely attributed to chemi  cal exposure 
(Shackelford and Elwell 1999).
Although the induction of neoplasms after 
exposure to SDD was limited to the alimen-
tary tract, other data, including the toxicity to 
the erythron, provided evidence of systemic 
exposure and toxicity in male and female rats 
and mice exposed to Cr(VI) for 2 years. We 
also observed these lesions in the 3-month 
studies (NTP 2007).
As part of the NTP 2-year studies on 
SDD (NTP 2008a) and chromium picolinate 
monohydrate (CPM) (NTP 2008b), which 
contains trivalent chromium [Cr(III)], total 
chromium content was determined in selected 
tissues and excreta of additional groups of 
male rats and female mice; these data will be 
presented in detail in an additional report. The 
goal of these studies was to examine the tissue 
uptake and distribution of Cr(VI) and Cr(III). 
Because Cr(VI) is reduced to Cr(III) both 
intracellularly and extracellularly and because 
analytical methods for the separate analysis 
of Cr(VI) or Cr(III) in biological samples are 
not available, the speciation of the tissue chro-
mium after exposure to Cr(VI) was inferred 
by comparing total chromium concentrations 
in tissues of rats and mice exposed to similar 
doses of Cr(VI) or Cr(III). After oral exposure 
to Cr(VI), chromium accumulation was cor-
related with exposure concentration and dura-
tion in several tissues (NTP 2008a). Similar 
doses of Cr(VI) and Cr(III) resulted in signifi-
cantly higher tissue chromium concentrations 
with Cr(VI), indicating that chromium was 
absorbed and distributed to tissues of rats and 
mice as Cr(VI); these data are consistent with 
previous studies (Costa 1997; Costa and Klein 
2006). The tissue concentration data were 
consistent with linear or supralinear (decreas-
ing rate of response with increasing dose) dose 
responses. In the present studies, neither the 
oral cavity nor the small intestine was collected 
for total chromium analysis. However, other 
reports suggest that Cr(VI) is also likely to be 
absorbed in the small intestine to a greater 
extent than Cr(III) (Donaldson and Barreras 
1966; Febel et al. 2001).
Reduction of Cr(VI) to the less perme-
able and bioavailable Cr(III) is thought to 
occur primarily in the stomach, as a mecha-
nism of detoxification. Gastric reduction has 
been hypothesized to be efficient, such that 
oral exposure to Cr(VI) would not result in 
toxicity or carcinogenicity, except perhaps in 
the stomach (De Flora 2000; De Flora et al. 
1997; Proctor et al. 2002). Notably, in the 
2-year study, no neoplasms or nonneoplastic 
lesions were observed in the forestomach or 
glandular stomach of rats or mice. However, 
the observed increases in neoplasms of the 
small intestine of mice and the toxicity to the 
erythron, histiocytic infiltration, and uptake 
of Cr(IV) into tissues of rats and mice suggest 
that, under the conditions of this study, at 
least a portion of the administered Cr(VI) was 
not reduced in the stomach. The significant 
disparity in the oral toxicity and carcinogenic-
ity of Cr(VI) and Cr(III) in rodents, includ-
ing the absence of increases in neoplasms or 
nonneoplastic lesions of the small intestine in 
rats or mice exposed to CPM (NTP 2008b), 
provides additional evidence that Cr(VI) is 
not completely reduced in the stomach and is 
responsible for the observed effects.
Recently, De Flora et al. (2008) have 
suggested that increases in neoplasms of the 
small intestine observed in mice in the pres-
ent study are the result of saturation of the 
gastric reduction capacity. If such a threshold 
mechanism were to occur, the dose that satu-
rated the reducing capacity would likely rep-
resent an inflection point on a sublinear dose 
response curve, with doses above the inflec-
tion point demonstrating an increasing rate 
of response per unit dose, because unreduced 
chromium would be transported into tissues. 
However, when we tested tissue concentration 
and mouse small intestine neoplasm data for 
linearity, data that were statistically nonlinear 
were supra  linear (decreasing rate of response 
per unit dose).
A reduction capacity of about 84–88 mg 
Cr(VI)/day has been estimated for human gas-
tric juice (De Flora et al. 1997). This estimate 
was based on reported values of human secre-
tion of gastric fluid per day during fasting and 
after consuming three meals per day in com-
bination with experimental data on reduction 
of Cr(VI)/mL of gastric juice produced during 
these periods. Similar data are not available 
for Cr(VI) reduction by mouse gastric juice. 
However, assuming that Cr(VI) reduction is 
equally effective in mice and humans and that 
gastric secretion scales across species by body 
weight3/4, then the Cr(VI) reduction capac-
ity of gastric juice from a 50-g mouse would 
be approximately 0.4 mg/day (~ 8 mg/kg/
day). This value is greater than all of the male 
mouse doses and is nearly equivalent to the 
average daily dose of Cr(VI) in the high-dose 
group of female mice in the 2-year drinking 
water study of SDD (Table 1). Collectively, 
the dose–response analysis and gastric reduc-
tion capacity calculations indicate that SDD 
induced neoplasms in the small intestine of 
mice at dose levels that did not exceed the 
estimated Cr(VI) reducing capacity for gastric 
juices in mice.
Cr(VI) is genotoxic in a number of 
in vitro and in vivo test systems (De Flora 
et al. 1990; IARC 1990); however, the 
mecha  nisms of genotoxicity and carcinogenic-
ity are not fully understood. Because Cr(VI) 
as chromate structurally resembles sulfate and 
phosphate, it can be taken up by all cells and 
organs throughout the body through non-
specific anion transporters (Costa 1997). 
Once inside the cell, indirect DNA damage 
may occur through the generation of oxy-
gen radicals during intracellular reduction of 
Cr(VI) through the more reactive pentavalent 
and tetravalent chromium to Cr(III) (O’Brien 
et al. 2003); however, evidence of the role of 
reactive oxygen species in the genotoxicity of 
Cr(VI) is inconsistent (Chorvatovicova et al. 
1991; O’Brien et al. 2003; Standeven and 
Wetterhahn 1991; Zhitkovich 2005). Cr(III), 
the final product of intracellular reduction of 
Cr(VI), has been shown to interact directly 
with DNA and other macromolecules to 
induce chromosomal alterations and muta-
tional changes (O’Brien et al. 2003; Quievryn 
et al. 2006; Reynolds et al. 2007; Zhitkovich 
2005). DNA adducts, DNA–protein cross-
links, and DNA interstrand cross-links have 
all been identified as products of Cr(III)–
DNA interactions. The relative contributions 
of the multiple, complex pathways of chro-
mium-induced genotoxicity continue to be 
investigated.
In conclusion, the NTP 2-year study of 
SDD is the first and only lifetime study that 
clearly demonstrates the carcinogenicity of 
Cr(VI) in rats and mice after oral exposure. 
In addition, the hematology, histologic and 
tissue distribution data provide evidence of 
systemic exposure in rats and mice.
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